LYNDA MILLER: Open Payments
NPI 1104177997 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,912 in 94 payments from 16 companies in 2025. Trend: 2023 $1,625 · 2024 $2,100 · 2025 $1,912
Food & beverage: $1,912
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $473 |
| Novo Nordisk Inc | 20 | $445 |
| Axsome Therapeutics, Inc. | 9 | $182 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $153 |
| Supernus Pharmaceuticals, Inc. | 6 | $112 |
| AstraZeneca Pharmaceuticals LP | 5 | $101 |
| Astellas Pharma US Inc | 4 | $90 |
| PFIZER INC. | 3 | $65 |
| Lilly USA, LLC | 3 | $59 |
| Phathom Pharmaceuticals, Inc. | 2 | $53 |
Products named: Ozempic, Auvelity, UBRELVY, VRAYLAR, CAPLYTA, QULIPTA, Wegovy, Qelbree.
Industry payments across VA — which companies pay providers there.
